FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test

Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test.

http://www.fda.gov/drugs/drug-approvals-and-databases/fda-disco-burst-edition-lo...

Source: FDA Center for Drug Evaluation and Research - What's New - March 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news